Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement

Basit Öğe Kaydı
dc.authoridOz Puyan, Fulya/0000-0001-5853-0109
dc.authoridAktas, Gokmen/0000-0003-4199-6943
dc.authoridOktay, Cemil/0000-0002-1595-8014
dc.authoridkus, tulay/0000-0001-5781-4820
dc.authorwosidOz Puyan, Fulya/A-7077-2018
dc.authorwosidAktas, Gokmen/AAN-4731-2020
dc.authorwosidPuyan, Fulya Oz/A-7804-2016
dc.authorwosidOktay, Cemil/ABR-3737-2022
dc.authorwosidkus, tulay/JOZ-3660-2023
dc.contributor.authorKus, Tulay
dc.contributor.authorAktas, Gokmen
dc.contributor.authorOktay, Cemil
dc.contributor.authorPuyan, Fulya Oz
dc.contributor.authorTastekin, Ebru
dc.date.accessioned2024-06-12T10:51:10Z
dc.date.available2024-06-12T10:51:10Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractRearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3-5% of non-small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens the door to new treatment strategies.en_US
dc.identifier.doi10.1097/CAD.0000000000001272
dc.identifier.endpage405en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue4en_US
dc.identifier.pmid35171116en_US
dc.identifier.scopus2-s2.0-85126388912en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage400en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001272
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18271
dc.identifier.volume33en_US
dc.identifier.wosWOS:000766755300009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAlk Fusionen_US
dc.subjectBreast Canceren_US
dc.subjectCrizotiniben_US
dc.subjectTriple-Negativeen_US
dc.subjectTreatmenten_US
dc.subjectCell Lung-Canceren_US
dc.titleDramatic response to crizotinib in a breast cancer patient with ALK gene rearrangementen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu